Semax Research: The ACTH(4-10) Analogue and Its Published Findings

Semax is a synthetic heptapeptide analogue of ACTH(4-10). What rodent studies report on BDNF signalling and gene expression after ischemia, and the limits.

Share
Semax Research: The ACTH(4-10) Analogue and Its Published Findings

Semax is a synthetic seven-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was designed as an analogue of a short fragment of adrenocorticotropic hormone (ACTH), and it has been studied mainly by research groups in Russia since the 1980s. For laboratories, Semax is interesting because it separates some of the neuroactive properties attributed to ACTH fragments from the hormone's classic role in stimulating the adrenal cortex. This article covers where the peptide comes from, what the key published studies report and how to read that literature carefully.

Origins: from ACTH fragments to a stabilized heptapeptide

ACTH is a 39-amino-acid hormone cleaved from the precursor protein pro-opiomelanocortin (POMC). Work in the mid-20th century showed that short fragments of ACTH, lacking the sequence needed for adrenal stimulation, could still influence behaviour in animal models. The fragment ACTH(4-10) attracted particular attention in learning and attention research.

Short natural fragments like this are broken down quickly by peptidases. Semax was built by taking the ACTH(4-7) sequence (Met-Glu-His-Phe) and adding the tripeptide Pro-Gly-Pro at the C-terminus. Proline-rich sequences tend to resist enzymatic degradation, and the Pro-Gly-Pro (PGP) extension is generally described in the literature as a way to extend the peptide's activity. That design choice matters for interpreting studies: PGP is itself biologically active in some models, so well-designed experiments test PGP on its own as a comparison.

Key published research

BDNF and trkB signalling in the hippocampus

One of the most cited mechanistic studies is Dolotov and colleagues, published in Brain Research in 2006. The authors gave rats a single intranasal application of Semax and measured brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, trkB, in the hippocampus.

They reported a maximal 1.4-fold increase in hippocampal BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation (a marker of receptor activation), a 3-fold increase in BDNF exon III mRNA and a 2-fold increase in trkB mRNA. Treated animals also showed more conditioned avoidance reactions in a learning task. The authors suggested that Semax may influence cognitive function in rodents by modulating the hippocampal BDNF/trkB system.

The study is useful because it links a behavioural readout to a measurable molecular pathway. It is also limited: it used a single administration, short time points and one species.

Neurotrophin transcription after experimental ischemia

A 2010 study by Dmitrieva and colleagues in Cellular and Molecular Neurobiology looked at what happens to neurotrophins and their receptors in the rat cortex after permanent middle cerebral artery occlusion (pMCAO), a standard experimental stroke model. Importantly, the authors tested both Semax and the PGP tripeptide on its own.

Both compounds were reported to increase the transcription of neurotrophin and receptor genes, with partly overlapping profiles at 3, 24 and 72 hours. The authors concluded that Semax's effects on these genes were selective to the ischemic cortex, while the effect of PGP was mainly nonspecific. This is a good example of why the PGP control matters when reading Semax data.

Genome-wide expression in focal ischemia

Medvedeva and colleagues extended this work in a 2014 open-access paper in BMC Genomics. Using genome-wide transcriptional analysis of rat cortex after pMCAO, they compared Semax-treated animals with an "ischemia" control group at 3 and 24 hours.

The peptide mainly changed the expression of genes related to the immune system. Immune-response genes made up more than half of all the genes whose expression Semax changed, and genes encoding immunoglobulins and chemokines formed the most notable groups. The authors also reported changes in 24 vascular-system genes at 3 hours and 12 at 24 hours, involving processes such as endothelial development and migration and vasculogenesis. They proposed that immunomodulatory and vascular effects may underlie the neuroprotective activity seen in their models.

Limits of the evidence

Read the Semax literature with a few cautions in mind:

  • Mostly rodent models. The mechanistic findings summarized here come from rats. Gene-expression changes in an animal stroke model do not show what happens in other species or settings.
  • A concentrated research community. Much of the published work comes from a small number of connected groups. Independent replication from other laboratories is more limited than for many better-known peptides.
  • mRNA isn't function. Transcriptomic studies measure changes in gene expression. They don't on their own show changes in protein levels, cellular function or outcomes.
  • Short time windows. Many studies sample at hours to a few days after a single exposure.

None of the research above is evidence of effects in people. These are preclinical findings, reported here as published.

Research applications

In the published literature, Semax has been used as a tool to study:

  • Neurotrophin signalling (BDNF, NGF and their Trk receptors) in rodent brain tissue
  • Transcriptional responses in experimental ischemia models
  • Structure-activity questions about ACTH fragments and peptidase-resistant C-terminal extensions such as PGP

Characterization and handling

As with any short peptide, results depend on material quality:

  • Identity: confirm the molecular weight by mass spectrometry. Semax's sequence makes it straightforward to check against the expected mass.
  • Purity: HPLC purity on the batch certificate of analysis (see our guide to reading a peptide COA).
  • Storage: keep lyophilized material cold, dry and protected from light, and avoid repeated freeze-thaw cycles once it's in solution (see how to store research peptides).
  • Controls: include a PGP-only arm where the question involves the C-terminal extension, as the ischemia studies above did.

Frequently asked questions

What is Semax made of? It is a heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro: the ACTH(4-7) sequence plus a C-terminal Pro-Gly-Pro extension.

Is Semax the same as ACTH? No. It is a short synthetic analogue based on a fragment of ACTH. It lacks the part of the hormone associated with adrenal stimulation.

What has Semax research mainly measured? In the studies summarized here, neurotrophin signalling (BDNF/trkB) and gene expression in rat brain, including after experimental ischemia.

Why do studies include PGP on its own? Because the Pro-Gly-Pro tripeptide has activity of its own. Testing it separately helps show which effects belong to the full peptide.

For research supply questions, use the contact page.

References

  • Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. PMID: 16996037.
  • Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology. 2010;30(1):71-79. PMID: 19633950.
  • Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.

For research use only. Not for human consumption.